Benmu Biotech secures Taiwan’s first swine bivalent vaccine license, aiming to capture Southeast Asia’s billion dollar market with innovative livestock solutions.
Adimmune Corporation, long recognized for human vaccines, has officially entered the animal vaccine sector through it subsidiary, Benmu Biotech. The company’s bivalent vaccine against Porcine Circovirus (PCV) and Mycoplasma Hyopneumoniae (M.Hyo) co‑developed with Taiwan’s Agricultural Technology Research Institute, received approval from the Ministry of Agriculture in late July. This marks Adimmune’s first animal vaccine license and a strategic pivot toward livestock health, reported BigGo Finance.
Field trials conducted at National Pingtung University of Science and Technology showed promising results. Piglets vaccinated with the new vaccine demonstrated higher survival rates, improved weight gain, and stronger disease resistance compared to existing monovalent options. These outcomes highlight the vaccine’s potential to reshape swine health management in Asia.
The global animal vaccine market exceeded USD 13 billion in 2025, with livestock vaccines accounting for nearly two‑thirds of sales. Within this, swine vaccines represent USD 1.6–2 billion annually, and Asia alone contributes about USD 1 billion. With more than half of the world’s pigs concentrated in Asia, demand for effective multivalent vaccines is expected to grow at double‑digit rates.
Benmu Biotech General Manager Hung Yueh‑Peng emphasized that PCV represents over 55% of swine vaccine sales, forming a logical base for multivalent development. By combining PCV with swine enzootic pneumonia (SEP), primarily caused by M.Hyo, the company tackles two major infectious piglet diseases.
Benmu Biotech is not stopping at the bivalent vaccine. The company is already working on a trivalent vaccine incorporating Porcine Reproductive and Respiratory Syndrome (PRRS), aiming to reduce piglet mortality with a single dose after birth. Beyond vaccines, Benmu is exploring animal interferons and monoclonal antibodies to broaden its portfolio.
To meet anticipated demand in Southeast Asia, Benmu plans to begin factory construction and fundraising in 2027. The company is targeting tens of millions of doses for markets in the Philippines, Vietnam, and Thailand, where pig farming is most concentrated. This expansion underscores confidence in the vaccine’s competitiveness and scalability.
Benmu Biotech, founded in 2018, diversified Adimmune’s portfolio beyond human vaccines. Securing this license validates its research capabilities and opens a new growth driver for the group. For Adimmune, the move represents a calculated entry into a sector with strong regional demand and long‑term growth potential.
Adimmune and Benmu are positioning themselves as leading players in Asia’s swine health market. Their success could set a precedent for other human vaccine companies seeking diversification into animal health.
Subscribe now to the technical pig magazine
AUTHORS
Bifet Gracia Farm & Nedap – Automated feeding in swine nurseries
The importance of Water on pig farms
Fernando Laguna Arán
Microbiota & Intestinal Barrier Integrity – Keys to Piglet Health
Alberto Morillo Alujas
Impact of Reducing Antibiotic use, the Dutch experience
Ron Bergevoet
The keys to successful Lactation in hyperprolific sows
Mercedes Sebastián Lafuente
Addressing the challenge of Management in Transition
Víctor Fernández Segundo
Dealing with the rise of Swine Dysentery
Roberto M. C. Guedes
Actinobacillus pleuropneumoniae – What are we dealing with?
Marcelo Gottschalk
The new era of Animal Welfare in Pig Production – Are we ready?
Antonio Velarde
Gut health in piglets – What can we do to measure and improve it?
Alberto Morillo Alujas
Interview with Cristina Massot – Animal Health in Europe after April 2021
Cristina Massot
Differential diagnosis of respiratory processes in pigs
Desirée Martín Jurado Gema Chacón Pérez
